2Ghimire G,Gupta A,Hage FG.Guidelines in review:2013ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.J Nucl Cardiol,2014,21:190-201.
5Thomas D,Giugliano RP.Management of ST-segment elevation myocardial infarction:Comparison of the updated guidelines from North America and Europe.Am Heart J,2009,158:695-705.
6Claeys MJ,de Meester A,Convens C,et al.Contemporary mortality differences between primary percutaneous coronary intervention and thrombolysis in ST-segment elevation myocardial infarction.Arch Intern Med,2011,171:544-549.
7Busk M,Maeng M,Rasmussen K,et al.The Danish multicentre randomized study of fibrinolytic therapy vs.primary angioplasty in acute myocardial infarction(the DANAMI-2 trial):outcome after3 years follow-up.Eur Heart J,2008,29:1259-1266.
9Antman EM,Anbe DT,Armstrong PW,et al.ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary.A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to revise the1999 guidelines for the management of patients with acute myocardial infarction).J Am Coll Cardiol,2004,44:671-719.
10Flynn A,Moscucci M,Share D,et al.Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Arch Intern Med,2010,170:1842-1849.
3DE LEMOS J A, BLAZING M A, WIVIOTT S D, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial[J]. JAMA, 2004,292 : 1307 -1316.
4ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary[J]. Circulation, 2004,110 : 588-636.
5ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction[J], Circulation, 2007, 116 : e148-e304.
6TIMI IIIB Investigators. Effects of tissue plasmino gen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction[J]. Circulation, 1994 1545-1556.
7COLIN BAIGENT, RORY COIAANS, PAUL AP- PLEBY, et al. ISIS-2:10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither[J]. BMJ,1998,316: 1337-1343.
8Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial:a randomised controlled trial [ J ]. Lancet, 2002, 360:1189-1196.
9The CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mor tality in patients with acute ST-segment elevation myocardial infarction[J]. JAMA, 2005,293 : 437-446.
10The Heart Outcome Prevention Evaluation Study Investigator. Effects of an angiotensimconverting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients[J]. N Engl J Med, 2000,342 : 145-153.
2Sinha MK,Roy D,Gaze DC,et al.Role of 'Ischemia modified albumin', a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emergency Medicine . 2004
3Chen Gang,Khalil Nasreen.In vitro wounding of airway smooth muscle cell monolayers increases expression of TGF-beta receptors. Respiration Physiology . 2002
